Compare Biogen Inc (BIIB) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Under Armour Inc Class A — how do they compare? Biogen Inc trades at $206.5 (market cap $30.13B), while Under Armour Inc Class A trades at $5.16 (market cap $2.26B). The key difference: Biogen Inc is far larger — about 13.3× Under Armour Inc Class A's market cap, and Biogen Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| BIIB | UA | |
|---|---|---|
Market Cap | $30.13B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $7.88 |
52-Week Low | $128.93 | $3.96 |
Enterprise Value | $37.20B | $3.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Under Armour (UA) trades at $5.20, down 8.37% amid weak quarterly results and lowered revenue guidance. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal declining revenue ($5.16B in 2025 to $4.9B in 2026) and negative profitability (net margin -9.99%). Recent news highlights softer consumer demand in key markets, though the company maintains its profitability outlook.
The outlook remains challenging with significant execution risks and competitive pressures. While analyst sentiment is mixed (38.81% Buy, 49.25% Hold), the stock's deep value metrics (P/S 0.45) may attract contrarian investors if operational improvements materialize. Key risks include sustained revenue declines and negative cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
